MR. ERCK: Mr. President, Mr. Vice President, thank you for saving the most exciting company for the last. (Laughter.) So we’re Novavax. We’re down the street in Maryland. We’re a vaccine company. We make the recombinant nanoparticles. We make respiratory vaccines. We have two in phase three trials. We have an RSV vaccine, where we vaccinated 4,600 pregnant women to protect infants from RSV disease and the youngest kids.
We have a flu vaccine. We all know we need a better flu vaccine and we have one in phase three trials. We’re going to unblind in four weeks. It’s an exciting time for the company.
But we actually — our company is focused on emerging infectious diseases. We’ve made two coronavirus vaccines. We made one for SARS. We made one for MERS. We tested MERS and — all the way through animal challenge trials and it showed 100 percent infection protection.
We have an Ebola vaccine that what the NIH showed, in four different nonhuman primate studies, that we had 100 percent protection at extremely low doses.
And we’ve made a pandemic flu vaccine for H7 and 9 and others. And we’ve twice now taken from the gene sequence to the first in human studies done in the 90 days and published it in the New England Journal. And we’re once again doing the same thing since the gene sequence was identified — I think it published on January 10th. We’ve taken the same recombinant nanoparticle platform and have been in animal studies for a couple of weeks. We expect data this week on — from one of them.
THE PRESIDENT: On this? On corona?
MR. ERCK: And on this — I’m sorry, on corona. Yes. And we’re going to the nonhuman primates this week with the coronavirus vaccine candidate.
THE PRESIDENT: So what do you think in terms of timing? What do you do think?
MR. ERCK: Timing is — what you hear around the table. As soon as we can get it to humans in the May-June timetable and in phase one study (inaudible) but we’ll have primate data.
THE PRESIDENT: So those are unheard of speeds, I think. Right? Pretty much. We’ll make it very easy for you. Those are — and we have to be very safe. But those are unheard of speeds.
Go ahead, please.
MR. ERCK: No, and we’re trying to identify scale so that we can get to the billion (inaudible) scale both for — we have the vaccine antigen and adjuvant. And you put those together and you get the most promising result, we think. And so we desperately need and have good relationships with the FDA and to work with the FDA to see where, instead of waiting 30 days, for — to get to an IND, you get in 10 days or 21 — whatever the number is. But there are a lot of things that we can do with the FDA.
And, frankly, we need money. We’re a biotech company, and not one of the larger pharma companies. And so we need money to get scale.
THE PRESIDENT: But you work with the other companies also?
MR. ERCK: And we have worked with the other companies and on this particular instance, we have not yet. But we can.
Market Data 
Markets 
AI
